Unfortunately the timelines for a license deal with the likes of Perrigo, or a settlement with J&J don't match up with the current offer on the table. The only way, in my opinion, to deal with that is to begin raising the price of the acquisition. In my humble opinion the BOD was smart, they designated a class of Preferred stock that would be there just in case of these types of unforeseen events. Companies often do these things. I suspect iHub's alydyr will get his wish and that class of Preferred stock will be used.

I also think there will be additional offers. Shareholders, at least those shareholders who still remember how to read, should really take a look at ISO 15197:2015. Within two years the industry standard for at home testing devices will be changed from the current +/- 15% mg/dl 95% of the time to +/- 12% mg/dl 98% of the time, and +/- 14% 99% of the time. On the current market that would leave Roche Aviva Plus and Lifescan Verio as the only two products that meet that criteria.

Oh yes, and GenPrecis which blows out the standard. The perfect deal would be a settlement with J&J and the sale/license of GenPrecis to Lifescan. But that won't happen because of the J&J NIH philosophy which while in use has allowed them to give away half of their market.